



# Market Announcement

21 May 2018

---

## Actinogen Medical Limited – Trading Halt

### Description

The securities of Actinogen Medical Limited (the 'Company') will be placed in trading halt at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 23 May 2018 or when the announcement is released to the market.

---

<b>Security Code:</b>	ACW
-----------------------	-----

---

### Issued by

**Madeleine Green**

Adviser, Listings Compliance (Perth)



21 May 2018

Ms Anjuli Sinniah  
ASX Operations  
Level 40 Central Park  
152-158 St George's Terrace  
PERTH WA 6000

*Via Email*

Dear Anjuli

## Trading Halt Request

In accordance with ASX Listing Rule 17.1, the Company hereby requests that its securities be placed into an immediate trading halt pending an announcement regarding the release of information pertaining to the interim analysis.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Wednesday, 23 May 2018, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely

A handwritten signature in black ink, appearing to read "Peter Webse", is positioned above the typed name.

**Peter Webse**  
Company Secretary

### About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

### **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**